Metastatic Colorectal Cancer
Clinical research in refractory metastatic colorectal cancer with liver-dominant disease focuses on treatments aimed at controlling tumour growth in the liver and limiting hepatic progression.
- Hepatic progression-free survival
- Bevacizumab
- Trifluridine-tipiracil
The therapeutic interest centres on advanced gastrointestinal oncology and disease control in patients with limited options after prior treatment.
Metastatic Breast Cancer
Research in refractory metastatic breast cancer with liver-dominant involvement addresses hepatic disease burden and treatment resistance in advanced breast cancer.
- Eribulin
- Vinorelbine
- Capecitabine
This area reflects a focus on systemic therapy options used to manage progressive hepatic metastases in the oncology setting.
Liver-Dominant Metastatic Disease
The sponsor’s research landscape is concentrated on cancers with predominant spread to the liver, where treatment goals include improving local disease control and delaying hepatic progression.
- Hepatic tumour control
- Metastatic disease management
- Advanced solid tumours
This includes both colorectal and breast cancer populations with significant liver metastases.
Hepatic Cancer Treatment Strategies
Investigations involve treatment approaches designed for hepatic-dominant metastatic cancer, with attention to combinations used after prior therapy in difficult-to-treat disease.
- Combination therapy
- Post-treatment disease control
- Advanced oncology care
The clinical focus remains on cancers where the liver is the main site of progression and therapeutic need.
